Foghorn Therapeutics (FHTX) Preferred Stock Liabilities (2019 - 2020)
Foghorn Therapeutics (FHTX) posted quarterly Preferred Stock Liabilities of $176.4 million for Q3 2020, up 103.83% quarter-over-quarter from $86.5 million in Q4 2019.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Foghorn Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $176.4 million for Q3 2020.
- In Q3 2020, Preferred Stock Liabilities changed N/A year-over-year to $176.4 million; the TTM figure through Sep 2020 stood at $176.4 million (changed N/A YoY), while the FY2019 annual figure was $86.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2020 stood at $176.4 million, up from $86.5 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $176.4 million in Q3 2020, with the low at $86.5 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Foghorn Therapeutics | 347.14 Mn | 279.06 Mn | - | - |